NCT07614256 Multimodal Imaging and Digital Pathology for Prostate Cancer Prediction
| NCT ID | NCT07614256 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Guangxi Medical University |
| Condition | Prostate Cancer (Diagnosis) |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2025-05-30 |
| Primary Completion | 2030-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2025-05-30 with a primary completion date of 2030-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a multicenter observational study. A deep learning model integrated with multimodal imaging and digital pathology spatial registration is built based on preoperative multiparametric magnetic resonance imaging, transrectal ultrasound and postoperative digital pathological whole slide images. The study is designed to achieve accurate prediction of clinically significant prostate cancer and non-invasive risk stratification. Unnecessary prostate biopsy and overdiagnosis can be reduced to support the optimization of clinical diagnosis and treatment strategies.
Eligibility Criteria
Inclusion Criteria: 1. Subjects who are scheduled to undergo or have undergone prostate biopsy or radical prostatectomy. 2. Subjects who have completed standard-of-care preoperative multiparametric MRI (mpMRI) and transrectal ultrasound (TRUS) examinations. 3. Subjects with complete pathological diagnosis results available. 4. Age between 40 and 90 years. 5. Able and willing to provide written informed consent (for prospective cohort participants only). Exclusion Criteria: 1. Prior history of pelvic radiation therapy or radical prostatectomy. 2. Incomplete or poor-quality mpMRI or TRUS images (e.g., motion artifacts, insufficient sequences). 3. Concurrent other primary malignant tumors. 4. Severe systemic diseases that may affect the evaluation of the prostate. 5. Subjects with incomplete clinical or pathological data. 6. Contraindications to MRI examination (e.g., incompatible metallic implants, severe claustrophobia).
Contact & Investigator
Fubo Wang, MD
PRINCIPAL INVESTIGATOR
Guangxi Medical University
Frequently Asked Questions
Who can join the NCT07614256 clinical trial?
This trial is open to male participants only, aged 40 Years or older, up to 90 Years, studying Prostate Cancer (Diagnosis). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07614256 currently recruiting?
Yes, NCT07614256 is actively recruiting participants. Contact the research team at shicaigou@sr.gxmu.edu.cn for enrollment information.
Where is the NCT07614256 trial being conducted?
This trial is being conducted at Liuzhou, China.
Who is sponsoring the NCT07614256 clinical trial?
NCT07614256 is sponsored by Guangxi Medical University. The principal investigator is Fubo Wang, MD at Guangxi Medical University. The trial plans to enroll 3,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.